IDO1 and PD-L1 are co-expressed in a number of cancers [20–23], and preclinical studies have demonstrated the additive or synergistic effects of combined inhibition of IDO1 and PD-L1 [19, 24]. The gene discussed is IDO1; the disease is cancer.